Blackrock Health Sciences Trust
| NYSE: BME | Financial Services / Asset Management / USA |
| 41.86 | +0.4800 | +1.16% | Vol 38.04K | 1Y Perf -9.09% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 40.60 | ASK | 42.83 | ||
| Open | 41.62 | Previous Close | 41.38 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 69.40 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | ★★★★+ 56.93 | |
| Price Range Ratio 52W % | 40.94 | Earnings Rating | — | |
| Market Cap | 580.18M | Earnings Date | - | |
| Alpha | 0.00 | Standard Deviation | 0.05 | |
| Beta | 0.76 |
Today's Price Range 41.4942.06 | 52W Range 38.2747.04 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.08% | ||
| 1 Month | -1.60% | ||
| 3 Months | -3.95% | ||
| 6 Months | 7.83% | ||
| 1 Year | -9.09% | ||
| 3 Years | 24.47% | ||
| 5 Years | 19.60% | ||
| 10 Years | 71.99% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 9.49 | |||
ROE last 12 Months | 27.60 | |||
ROA (5Y Avg) | 7.26 | |||
ROA last 12 Months | 8.37 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | -0.10 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 22.50 | ||||
| 4.50 | ||||
| -9.29 | ||||
| 15.90 | ||||
| -31.30 | ||||
| -0.29 | ||||
| 1.20 | ||||
| 35.90 | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| 99.10 | ||||
| 98.99 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -62 046 100.00 | ||||
| -4.60 | ||||
| 38.01 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.99 | ||||
| 2.56 | ||||
| 0.81 | ||||
| - | ||||
| Payout ratio | 34.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 38.04K |
| Shares Outstanding | 13.86K |
| Shares Float | 13.33M |
| Trades Count | 388 |
| Dollar Volume | 1.59M |
| Avg. Volume | 30.03K |
| Avg. Weekly Volume | 29.44K |
| Avg. Monthly Volume | 32.97K |
| Avg. Quarterly Volume | 27.69K |
Blackrock Health Sciences Trust (NYSE: BME) stock closed at 41.86 per share at the end of the most recent trading day (a 1.16% change compared to the prior day closing price) with a volume of 38.04K shares and market capitalization of 580.18M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Asset Management industry, Financial Services sector and employs 0 people. Blackrock Health Sciences Trust CEO is John M. Perlowski.
The one-year performance of Blackrock Health Sciences Trust stock is -9.09%, while year-to-date (YTD) performance is -3.95%. BME stock has a five-year performance of 19.6%. Its 52-week range is between 38.27 and 47.04, which gives BME stock a 52-week price range ratio of 40.94%
Blackrock Health Sciences Trust currently has a PE ratio of 22.50, a price-to-book (PB) ratio of 4.50, a price-to-sale (PS) ratio of -9.29, a price to cashflow ratio of 15.90, a PEG ratio of 2.32, a ROA of 8.37%, a ROC of -% and a ROE of 27.60%. The company’s profit margin is 98.99%, its EBITDA margin is -%, and its revenue ttm is $-62 046 100.00 , which makes it $-4.60 revenue per share.
Of the last four earnings reports from Blackrock Health Sciences Trust, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Blackrock Health Sciences Trust’s next earnings report date is -.
The consensus rating of Wall Street analysts for Blackrock Health Sciences Trust is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Blackrock Health Sciences Trust stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Blackrock Health Sciences Trust has a dividend yield of 5.99% with a dividend per share of $2.56 and a payout ratio of 34.00%.
Blackrock Health Sciences Trust has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.93, ATR14 : 0.73, CCI20 : 126.78, Chaikin Money Flow : -0.23, MACD : -0.13, Money Flow Index : 68.23, ROC : 5.36, RSI : 57.69, STOCH (14,3) : 92.93, STOCH RSI : 0.95, UO : 58.83, Williams %R : -7.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Blackrock Health Sciences Trust in the last 12-months were:
Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
CEO: John M. Perlowski
Telephone: +1 800 882-0052
Address: 100 Bellevue Parkway, Wilmington 19809, DE, US
Number of employees: 0
